Welcome to the website of the New Diagnostics Working Group

The New Diagnostics Working Group (NDWG) is one of the seven working groups of the Stop TB Partnership. It supports the Partnership in its goal of eliminating tuberculosis (TB), in particular by promoting the development and evaluation of new TB diagnostic tools. The NDWG is a network of experts representing stakeholders from academia, NGOs, multilaterals and governmental institutions, TB high-burden countries, industry, and the patient community.


NDWG launches consultation on draft TPP for next-generation DST

The New Diagnostics Working Group and its Task Force on Next-Generation Sequencing and DST are conducting an online consultation on the draft Target Product Profile (TPP) for Next-Generation Drug-Susceptibility Testing at Peripheral Centres.

The online survey will enable to gather input from a large group of stakeholders representing researchers, high-burden countries, governmental and non-governmental organizations, test developers and the patient community. Participants will have the opportunity to evaluate the key performance and operational characteristics, in order to inform the update of the High-priority target product profiles for new tuberculosis diagnostics and build consensus around the updated version of the TPP.

Since the first release of this document in 2014, WHO issued updated treatment guidelines for multidrug- and rifampicin-resistant TB to reflect landmark changes in MDR treatment regimens. To ensure that relevant guidance be provided to drug developers, the drug prioritization and related assumptions for the other characteristics in the TPP were revised accordingly.

Draft TPP

More information about the NDWG Task Force on NGS

The NDWG releases factsheet on next-generation WGS to support its introduction in TB endemic countries

On the occasion of World TB Day, the NDWG releases a new factsheet “Next-generation Whole Genome Sequencing for TB control. A rapid and accurate diagnostic tool for better treatment and prevention”. By providing key information in an accessible way for a non-scientific audience, the document aims to improve broad understanding of the benefits of adopting Next-generation Whole Genome Sequencing (NG-WGS) in TB diagnosis, thus ultimately fostering its introduction into clinical practice in low- and middle-income countries with a high burden of drug-resistant TB.

WGS based on novel sequencing technologies has great potential for rapidly identifying the bacteria complete drug resistance profile and for enabling clinicians to select the best anti-TB treatment regimen, thus improving patient outcomes and reducing the spread of the disease. Moreover, NG-WGS makes it possible to understand transmission patterns with more accuracy, thereby improving the effectiveness of public health interventions aimed at controlling and preventing the spread of TB.

Accelerating the adoption of Next-generation Whole Genome Sequencing (NG-WGS) for the rapid diagnosis of drug-resistant TB will lead to the delivery of personalized treatment and will increase survival rates. Moreover, it will improve the effectiveness of public health prevention and control strategies, thereby bringing the TB epidemic closer to an end.

Download Factsheet

Joint FIND and NDWG symposium

24 October 2018, The Hague, Netherlands

On 24 October, FIND and the New Diagnostics Working Group convened the TB diagnostics community at their annual symposium. The event was held back-to-back with the 49th Union World Conference in The Hague, Netherlands, and attracted an audience of above 300 delegates.

We were honoured to welcome Dr. Eric Goosby, UN Special Envoy on Tuberculosis. In his opening talk, he considered how the global community can translate the political commitments expressed in the UN High Level Meeting declaration into action with a focus on efforts to develop new diagnostics for ending the TB epidemic.

The detection gap of 3.6 million cases calls for the development and implementation of novel, more effective tools to enable early diagnosis of all forms of TB and stop individual suffering and ongoing transmission. Presenters reviewed progress made in the global TB diagnostics pipeline and exciting advances in R&D for new tests that have potential to improve TB diagnosis closer to patients.

The event included a panel discussion on the theme “A new priority for TB diagnosis: active case finding strategies to catalyse country efforts”. This session highlighted the key role of active case finding as a complementary strategy to passive approaches to ensure early diagnosis and treatment of TB patients and reduce transmission. Panelists discussed which risk groups should be screened as a priority and which interventions should be considered in order to maximize impact.

Presentations and recording

News Archive